Reversing anticoagulation

Join Dr Charles Pollack for a discussion of his cutting-edge study: Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey

Earn CME credits

In order to claim CME credits for watching the ‘Reversing anticoagulation’ module and receive a certificate, please register on our eLearning platform. Following a brief pre-assessment, you will be able to view the module and can subsequently take the post-assessment. Your certificate of accreditation will become available following this.

Access CME Module


Dr Charles Pollack

Thomas Jefferson University Hospital

Philadelphia, USA


While the preventative properties of NOACs for thrombotic events have been established, many clinicians have expressed reservations for use of NOACs due to the possibility of major bleeding. However, what if a safety net were available, enabling clinicians to administer NOACs more confidently? In this important Journal Club, Dr Charles Pollack will discuss the results of his recent study which show that the effects of the NOAC dabigatran, specifically the possibility of major bleeding, can be wholly and rapidly reversed by the monoclonal antibody idarucizumab.

view abstract  access full paper

  • Target audience

    This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.

  • Learning objectives

    After this activity, participants should be able to:

    • Describe how idarucizumab reverses the anticoagulation effects of dabigatran
  • Disclosures

    Prof John Camm:

    • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    • Consultant (retained) for: Boehringer Ingelheim
    • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer

    Dr Charles Pollack

    • Consultant for (non promotional): Boehringer Ingelheim, Janssen Pharma, BMS/Pfizer, Portola, Daiichi Sankyo, CSL Behring
    • Research support from: Boehringer Ingelheim, Janssen Pharma, Portola, Daiichi Sankyo, CSL Behring

    Staff and reviewer disclosures

    ACHL staff, PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Accreditation

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and PCM Scientific. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

    Credit designation

    The Academy for Continued Healthcare Learning designated this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Funding

    This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme.

    The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.